Since the completion of this clinical trial, PD-1 inhibitors, either as single agents or in combination with a CTLA-4 or a LAG-3 inhibitor, have replaced ipilimumab monotherapy as the standard of care for metastatic melanoma. This evidence concerns the gene LAG3 and metastatic melanoma.